Northwestern Mutual Investment Management Company LLC Raises Holdings in Edwards Lifesciences Corp (NYSE:EW)

Northwestern Mutual Investment Management Company LLC lifted its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 34.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,874 shares of the medical research company’s stock after buying an additional 2,772 shares during the period. Northwestern Mutual Investment Management Company LLC’s holdings in Edwards Lifesciences were worth $2,051,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Columbia Trust Co 01012016 increased its stake in Edwards Lifesciences by 1.1% in the 1st quarter. Columbia Trust Co 01012016 now owns 4,264 shares of the medical research company’s stock valued at $803,000 after purchasing an additional 47 shares in the last quarter. Coastal Investment Advisors Inc. increased its stake in Edwards Lifesciences by 13.5% in the 4th quarter. Coastal Investment Advisors Inc. now owns 454 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 54 shares in the last quarter. Intrust Bank NA increased its stake in Edwards Lifesciences by 0.8% in the 4th quarter. Intrust Bank NA now owns 6,682 shares of the medical research company’s stock valued at $1,559,000 after purchasing an additional 55 shares in the last quarter. Valeo Financial Advisors LLC increased its position in Edwards Lifesciences by 12.1% during the first quarter. Valeo Financial Advisors LLC now owns 528 shares of the medical research company’s stock worth $113,000 after buying an additional 57 shares in the last quarter. Finally, Cedar Brook Financial Partners LLC increased its position in Edwards Lifesciences by 2.3% during the first quarter. Cedar Brook Financial Partners LLC now owns 2,529 shares of the medical research company’s stock worth $477,000 after buying an additional 57 shares in the last quarter. 81.22% of the stock is owned by institutional investors and hedge funds.

Shares of Edwards Lifesciences stock opened at $218.81 on Friday. The company has a quick ratio of 2.47, a current ratio of 3.36 and a debt-to-equity ratio of 0.17. The firm has a market cap of $45.13 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.75 and a beta of 0.85. Edwards Lifesciences Corp has a fifty-two week low of $154.52 and a fifty-two week high of $247.64. The business has a 50-day moving average price of $212.94 and a 200 day moving average price of $222.43.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $1.51 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.29 by $0.22. The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.03 billion. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. Edwards Lifesciences’s quarterly revenue was up 13.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.32 earnings per share. As a group, equities research analysts anticipate that Edwards Lifesciences Corp will post 4.95 earnings per share for the current year.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 750 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $216.93, for a total value of $162,697.50. Following the completion of the transaction, the vice president now directly owns 18,318 shares in the company, valued at $3,973,723.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $202.34, for a total value of $4,623,469.00. Following the completion of the transaction, the chief executive officer now owns 69,976 shares of the company’s stock, valued at $14,158,943.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 95,878 shares of company stock valued at $20,047,408. 1.48% of the stock is owned by corporate insiders.

Several equities research analysts have recently issued reports on EW shares. Cowen decreased their price objective on Edwards Lifesciences from $275.00 to $250.00 and set an “outperform” rating on the stock in a report on Monday, April 20th. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $230.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Credit Suisse Group raised their price objective on Edwards Lifesciences from $260.00 to $262.00 and gave the stock an “outperform” rating in a report on Friday, April 24th. BTIG Research restated a “hold” rating on shares of Edwards Lifesciences in a report on Thursday, April 23rd. Finally, Goldman Sachs Group initiated coverage on Edwards Lifesciences in a report on Wednesday, February 12th. They set a “neutral” rating and a $253.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $247.52.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: What are the reasons investors use put options?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.